Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Malignant Pleural Mesothelioma
NCT00770120Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Dec 2008
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in malignant pleural mesothelioma (MPM), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival up to 3 years. Started Dec 2008; status: completed.
02
Drugs
everolimus
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00770120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770120.